Inhibition of ACVRL1 expression in transgenic tumour-bearing mice or treatment with ALK1-Fc fusion protein RAP-041 inhibits angiogenesis to delay tumour growth and progression (Cunha et al. 2010). Here, ALK is linked to neoplasm.